Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.
|Number of pages||2|
|Journal||Asian Journal of Pharmaceutical and Clinical Research|
|Publication status||Published - 01-04-2017|
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
- Pharmacology (medical)